Company Overview

CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.

View Detailed Stock Data

Stock Info

CYDY Symbol
OTCQB Market
Market Cap

Upcoming Events

Special Meeting of Stockholders

June 7, 2018

One Lowenstein Drive, Roseland, New Jersey 07068

9:30 am ET

Recent Events

Investment Community Conference Call

October 19, 2017 at 1:00 pm PT / 4:00 pm ET

Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).

View Press Releases

Recent News